AstraZeneca is paying CSPC Pharmaceutical $30 million upfront, backstopped by $540 million in development milestones and $1.2 billion tied to sales, for two preclinical kidney-disease drug candidates. Total deal value: $1.77 billion. CSPC disclosed the terms in a Hong Kong exchange filing this week.
That’s a 58-to-1 ratio of milestone money to cash on the table now, typical for a China-biotech option deal where the buyer pays almost nothing until the science clears. AstraZeneca holds an option for exclusive rights globally or just outside China, asset by asset, with CSPC keeping Chinese rights to one of the two candidates.
This is AstraZeneca’s fourth trip to the CSPC well since 2024: $100 million upfront for a cardiovascular candidate that year, $110 million plus $5.2 billion in milestones for oral chronic-disease drugs in 2025, then $1.2 billion upfront in May for eight weight-management programs worth up to $18.5 billion. AstraZeneca isn’t shopping the field. It’s treating CSPC like an outsourced discovery engine.
What the buyer gets: two shots at slotting into a renal franchise that already prints money. Farxiga, approved for chronic kidney disease among other indications, generated $2.2 billion in the first quarter, AstraZeneca’s best-selling drug. No new sales force needed if either candidate reaches market.
$30 million barely registers against that quarterly haul. The real question is whether four bets on CSPC ever produce a molecule that reaches Phase 1.
— Diana Kowalski